Article Text

Download PDFPDF

471 CD47 blockade as a targeted immune oncology agent in head and neck squamous cell carcinoma model
  1. Riyam Al Msari1,
  2. Robert Saddawi-Konefka1,
  3. Joseph Califano2,
  4. Shiqi Tang2 and
  5. Chad Phillips1
  1. 1Univeristy of California San Diego Health, La Jolla, CA, USA
  2. 2University of California, San Diego, San Diego, CA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Myeloid antigen presenting cells (APCs) are critical to PD-1 inhibition (PD1i) and radiotherapy responses in Head and Neck Squamous Cell Carcinoma (HNSCC), but are inhibited by the ‘don’t eat me’ immune checkpoint molecule CD47 overexpressed on tumor cells that interacts with SIRPα receptor found on myeloid cells, impeding their immune function. Evorpacept is a high affinity CD47 blocking fusion protein with a SIRPα binding domain coupled to an inactive Fc domain that avoids anemia and hematologic toxicities. We hypothesize that Evorpacept maximizes PD1i and tumor-targeted stereotactic body radiation therapy (SBRT) responses in HNSCC by expansion of tumor-antigen specifc cytotoxic T cells and enhancing antigen presentation by APCS.

Methods To explore this, we employed our tobacco-signature, orthotopic murine oral squamous cell carcinoma (OSCC) models, one of which matches the immune infiltrate and PD1i response of human OSCC and the other of which is immune-cold with no response to PD1i. We also used Selective CRISPR Antigen Removal (SCAR) lentiviral vector system to knock out CD47 from the model and eliminate the remaining immunogenic cas9 editing machinery. Using these models, we investigated the synergistic effects and immune mechanism of Evorpacept on PD1i and tumor-targeted SBRT responses.

Results First, we find that CD47 knock out from our OSCC preclinical model leads to complete tumor regression, emphasizing CD47 as an immune oncology target in HNSCC (figure 1). Then, we show that Evorpacept potentiates both PD1i and tumor-targeted SBRT responses and leads to durable immunity in our immune-responsive and immune-cold OSCC preclinical model (figure 2). Using IRDye-tagged Tilmanocept to map the tumor draining lymph nodes (tdLNs), we find that Evorpacept increases cytotoxic tumor-antigen specific T cells populations in the tdLNs and the tumor microenvironment (TME) with PD1i or tumor-targeted SBRT administration (figure 3). Lastly, within the tdLNs, we find increased tumor-specific antigen presentation by professional APCs, including macrophages, dendridic cells, and B-cells (figure 4).

Conclusions We demonstrate that Evorpacept synergizes with PD1i and tumor- targeted SBRT and enhances anti-tumor immunity by promoting APC tumor-specific antigen presentation from the TME to the tdLNS to prime and expand tumor-specific cytotoxic T cell populations. This work highlights CD47 as a bridge between innate and adaptive antitumor immunity in HNSCC (figure 5).

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.